Panelists agreed the yet-undefined MFN plan’s impacts are unlikely to have a major impact on drug makers in the near term.
Next-generation obesity drug development needs to focus on protecting organs and providing other medical benefit, AstraZeneca's Makar said.
The FDA’s Rare Disease Innovation Hub was set up with borrowed resources, but needs long-term investment to succeed, director Rick said.
The Commissioner’s National Priority Review Voucher program could create incentives for innovative therapies and ease investor concerns about the agency overall, analysts said, but it could also reduce the value of existing voucher programs.

BIO Notebook: MFN Pricing, Next-Gen Obesity R&D, FDA’s Rare Disease Hub & Reaction To Review Program

Updates From Day 3 Of BIO